SCHEMBL23583000

SCHEMBL23583000

COC(=O)C(C)(C)c1ccc(C(C)(C)C(N)=O)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.59
KMT2A Q03164 2/20 0.59
CNR1 P21554 1/20 0.47
CNR2 P34972 1/20 0.47
BRS3 P32247 1/20 0.43
KCNN4 O15554 2/20 0.42
KIF11 P52732 1/20 0.41
PLCG1 P19174 1/20 0.37
ALDH1A1 P00352 2/20 0.36
TP53 P04637 1/20 0.36
RAB9A P51151 1/20 0.36
POLB P06746 1/20 0.36
SRC P12931 1/20 0.35
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
LMNA P02545 2/20 0.35
ALOX15 P16050 1/20 0.35
APEX1 P27695 1/20 0.35
MAPK1 P28482 1/20 0.35
RECQL P46063 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8974321 0.89 CNR1 (0.54) MAPTKMT2ACNR1CNR2BRS3
SCHEMBL23582988 0.85 PARP10 (0.50) MAPTKMT2ACNR1CNR2BRS3
SCHEMBL363770 0.84 CNR1 (0.51) MAPTKMT2ACNR1CNR2BRS3
SCHEMBL5877921 0.83 MAPT (0.50) MAPTKMT2ACNR1CNR2BRS3
SCHEMBL23582517 0.83 BRS3 (0.49) MAPTKMT2ACNR1CNR2BRS3
Hydrochloric Acid SCHEMBL2330246 0.82 CNR1 (0.50) MAPTKMT2ACNR1CNR2BRS3
SCHEMBL3573740 0.82 CNR1 (0.53) MAPTCNR1CNR2BRS3KCNN4
SCHEMBL1107149 0.82 CNR2 (0.57) MAPTCNR1CNR2BRS3KCNN4
SCHEMBL23582691 0.80 CA2 (0.47) MAPTCNR1CNR2BRS3LMNA
SCHEMBL4673000 0.80 CNR1 (0.47) MAPTKMT2ACNR1CNR2BRS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637440-B2 Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof LG CHEM, LTD. (KR) 2026-05-26 US disclosed
CN-114901653-B Novel amide derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof 株式会社LG化学 2024-11-22 CN disclosed
EP-4074701-B1 NOVEL AMIDE DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF LG CHEMICAL LTD (KR) 2023-12-13 EP disclosed
EP-4074701-B1 NOVEL AMIDE DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF LG CHEMICAL LTD (KR) 2023-12-13 EP disclosed
US-20230101389-A1 NOVEL AMIDE DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF LG CHEM, LTD. (KR) 2023-03-30 US disclosed
EP-4074701-A1 NOVEL AMIDE DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF Lg Chem, Ltd. (KR) 2022-10-19 EP disclosed
CN-114901653-A Novel amide derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof 株式会社LG化学 2022-08-12 CN disclosed
WO-2021133038-A1 NOVEL AMIDE DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF 주식회사 엘지화학 2021-07-01 WO disclosed
WO-2021133038-A1 NOVEL AMIDE DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF 주식회사 엘지화학 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230101389-A1 NOVEL AMIDE DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF DGAT2, DGAT1, MOGAT2 MAPT 1900/4885KMT2A 572/4885CNR1 1395/4885
US-12637440-B2 Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof DGAT2, DGAT1, DLAT MAPT 4369/4885KMT2A 738/4885CNR1 474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.